Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs

Clinical and Experimental Immunology

Volumn 127, Issue 2, 2002, Pages 293-302

  Lytton, S D ^a   Berg, U ^b   Nemeth, A ^b   Ingelman Sundberg, M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoantibody; Cyclosporin A; CYP450; FK506; GST fusion proteins

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 ISOENZYME; ENZYME ANTIBODY; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; SANDOZ; TACROLIMUS; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EXPOSURE; ENZYME BINDING; FEMALE; GRAFT REJECTION; HETEROLOGOUS EXPRESSION; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFANT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVER MICROSOME; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROSIS; ONSET AGE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TOXICITY; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANTIBODY SPECIFICITY; ARYL HYDROCARBON HYDROXYLASES; AUTOANTIBODIES; AUTOANTIGENS; AZATHIOPRINE; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DRUG THERAPY, COMBINATION; EPITOPES; FEMALE; GRAFT REJECTION; HEPATITIS, TOXIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFANT; ISOENZYMES; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POSTOPERATIVE COMPLICATIONS; PREDNISONE; RECOMBINANT FUSION PROTEINS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TACROLIMUS;

EID: 0036130209     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01754.x     Document Type: Article

References (39)

1. Current trends in drug-induced autoimmunity
2. Protein targets of xenobiotic reactive intermediates
3. Tienilic acid-induced autoimmune hepatitis: Anti-liver and anti-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9
4. Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis
5. Epitope mapping studies with human anti-cytochrome P450 3A antibodies
6. Expression of autoantibodies to specific cytochromes P450 in a case of disulfiram hepatitis
7. Cytochrome P4502D6: Understanding an autoantigen
8. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1
9. Identification by molecular cloning of an autoantigen associated with Addison's disease as steroid 17α-hydroxylase
10. Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: Markers of high progression to clinical Addison's disease
11. Role of P glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
12. Autoantibodies against cytochromes P4503A and P4502E1 in alcoholics
13. Alternative cyclosporine metabolic pathways and toxicity
14. Nephrotoxicity of cyclosporin A and FK506: Inhibition of calcineurin phosphatase
15. FK506 (Tacrolimus) decreases the cytotoxicity of cyclosporin A in rat hepatocytes in primary culture: Implication of CYP3A induction
16. Effects of an immunosuppressive agent, tacrolimus (FK506), on the activities of cytochrome P-450-linked monooxygense systems in rat liver microsomes
17. Clinical pharmacology and therapeutic drug monitoring in neonates and children
18. Pharmacogenetics in pediatrics: Implications for practice in new frontiers in pediatric drug therapy
19. Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties
20. Expression of modified human cytochrome P450 1A1 in Escherichia coli: Effects of 5′ substitution, stabilization, purification, spectral characterization, and catalytic properties
21. Substrate-regulated, cAMP-dependent phosphorylation, denaturation, and degradation of glucocorticoid-inducible rat liver cytochrome P450 3A1
22. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily
23. Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography
24. Cleavage of structural properties during the assembly of the head of bacteriophage T4
25. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: Model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease
26. Presence of anti-FKBP12 autoantibodies in patients with liver allografts: Its association with allograft rejection
27. Bimodal distribution of renal cytochrome P450 3A activity in humans
28. Renal drug metabolism
29. Characterization of rat cytochrome P450 isozymes involved in the covalent binding of cyclosporin A to microsomal proteins
30. Drug-mediated inactivation of cytochrome P450
31. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease - Possible association with a steroid-resistant transplant rejection episode
32. CYP3A genetics in drug metabolism
33. Short term cyclosporine induces a remission of autoimmune hepatitis in children
34. Immunologic evaluation during the first year of life of infants born to cyclosporine-treated female kidney transplant recipients: Analysis of lymphocyte subpopulations and immunoglobulin serum levels
35. Developmental pharmacodynamics of cyclosporine
36. Sera of children with hepatitis C infection and anti-liver-kidney microsome 1 antibodies recognize different CYP2D6 epitopes than adults with LKM+/HCV+ sera
37. De novo autoimmune hepatitis after liver transplantation
38. Chronic rejection and chronic cyclosporin toxicity in renal allografts
39. Cyclosporin: Nephro-protective as well as nephrotoxic?